about
Role of antioxidant property of carvedilol in mild to moderate hypertensive patients: A prospective open-label studyHeart rate control with adrenergic blockade: clinical outcomes in cardiovascular medicineNovel treatment approaches in hypertensive type 2 diabetic patientsEffectiveness, safety and cost of drug substitution in hypertensionDirected evolution of RebH for site-selective halogenation of large biologically active molecules.Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT.Comparison of amlodipine with cilnidipine on antihypertensive efficacy and incidence of pedal edema in mild to moderate hypertensive individuals: A prospective study.Use of carvedilol in hypertension: an update.Synthesis of conjugated chitosan and its effect on drug permeation from transdermal patches.Taking diabetes to heart--deregulation of myocardial lipid metabolism in diabetic cardiomyopathy.Vasodilating versus first-generation β-blockers for cardiovascular protection.Filled carbon nanotubes in biomedical imaging and drug delivery.Carvedilol and antioxidant proteins in a type I diabetes animal model.Carvedilol protects against apoptotic cell death induced by cisplatin in renal tubular epithelial cells.Investigation of carvedilol-evoked Ca²+ movement and death in human oral cancer cells.Carvedilol-induced elevation in cytosolic free Ca(2+) level and apoptosis in SIRC corneal epithelial cells.Development and optimization of carvedilol orodispersible tablets: enhancement of pharmacokinetic parameters in rabbits.Late-Stage Diversification of Biologically Active Molecules via Chemoenzymatic C-H Functionalization.Efficacy of losartan and carvedilol on central hemodynamics in hypertensives: a prospective, randomized, open, blinded end point, multicenter study.Dual targeting of TNF-α and free radical toxic stress as a promising strategy to manage experimental polycystic ovary.Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management.
P2860
Q28830600-36D4C81F-C7E6-41D4-85F8-12B5472C7807Q33902610-EF89B5A1-FC6C-4248-8604-E7487815C241Q34023579-72EE14D0-F75C-42B7-9C84-91210E18D2C7Q34174844-35FFF292-A0A0-4203-9D2A-16E98A11726BQ34462524-12AD747C-1E36-45D8-B635-058FDBAE23EAQ34546377-236D06A6-C792-41E3-A5D5-D656E8DF9C73Q35423871-8919AE9F-4BBB-4516-9857-8067896AD441Q35997307-A6696AC0-F1C1-4ECD-A994-72BD531BE6E6Q37133860-CC5CE6D5-311A-4F18-B56F-0340023F468FQ37457580-D38946ED-7DAA-408F-AD2E-877C80FED4B6Q37995858-76AE3A20-54D3-4770-9F87-7232E8DECEB5Q38272176-90484250-F4D5-4424-8490-A536589ADD7FQ39224330-43719A42-1E91-4D46-AFDB-DECF2039A296Q39304222-2A3679EC-2587-4F94-980E-E15C5A0803D2Q39534972-330CFF8A-7C03-49F3-B7AF-2121EBDA91DDQ39760098-52BE12F0-E207-494D-8734-E6B2DA060C1BQ41124333-6134D8D4-A773-4C11-ABD8-C370773FDED3Q41966650-15D503EC-7381-4D64-A0D5-2651387627BEQ46671693-064D2BA2-DDCC-4511-BFD5-36B7660E6FBEQ46731252-8BBF6DEB-2569-4CA8-B70A-9EB0633D960CQ47566245-ED48D91F-F045-49ED-947B-423DF3B20BC7
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականին հրատարակուած գիտական յօդուած
@hyw
2008 թվականին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Carvedilol in hypertension treatment
@ast
Carvedilol in hypertension treatment
@en
Carvedilol in hypertension treatment
@nl
type
label
Carvedilol in hypertension treatment
@ast
Carvedilol in hypertension treatment
@en
Carvedilol in hypertension treatment
@nl
prefLabel
Carvedilol in hypertension treatment
@ast
Carvedilol in hypertension treatment
@en
Carvedilol in hypertension treatment
@nl
P2860
P921
P3181
P1476
Carvedilol in hypertension treatment
@en
P2093
Panagiotis C Stafylas
Pantelis A Sarafidis
P2860
P3181
P356
10.2147/VHRM.2008.04.01.23
P407
P577
2008-01-01T00:00:00Z